Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of baricitinib in adults with systemic lupus erythematosus
MOH_2019-07-15_007282Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in systemic lupus erythematosus (SLE) (3 arms), sponsored by Eli Lilly and Company. Planned start May 2019; status: not yet recruiting.
02
Drugs
baricitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2019-07-15_007282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-07-15_007282.